Redefining the role of biomarkers in heart failure trials: expert consensus document
Recommended Citation
Kramer F, Sabbah HN, Januzzi JJ, Zannad F, Peter van Tintelen J, Schelbert EB, Kim RJ, Milting H, Vonk R, Neudeck B, Clark R, Witte K, Dinh W, Pieske B, Butler J, Gheorghiade M. Redefining the role of biomarkers in heart failure trials: expert consensus document. 2017 May;22(3):263-277.
Document Type
Article
Publication Date
5-1-2017
Publication Title
Heart failure reviews
Abstract
Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.
Medical Subject Headings
Biomarkers; Clinical Trials as Topic; Consensus; Diagnostic Imaging; Disease Management; Heart Failure; Humans; Patient Selection
PubMed ID
28332132
Volume
22
Issue
3
First Page
263
Last Page
277
